Azusa Nagao

Dr. Azusa Nagao


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Thrombosis Research
Verified
Journal Article
Closed access
Azusa NagaoAzusa Nagao
Azusa Nagao
CYCindy H.T. Yeung
Cindy H.T. Yeung
FGFederico Germini
Federico Germini
TSTakashi Suzuki
Takashi Suzuki

17 January 2014 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
Azusa NagaoAzusa Nagao
Azusa Nagao
SNShoko Nakazawa
Shoko Nakazawa
HHHideji Hanabusa
Hideji Hanabusa
Multicentric Castleman disease (MCD) is a lymphoproliferative disorder caused by human herpesvirus 8 (HHV8) infection HIV associated MCD (HIV-MCD) presents with various clinical symptoms. Many HIV-negative MCD patients are often treated with anti-human interleukin-6 (IL6) receptor monoclonal antibodies (tocilizumab), and successful results have been reported. IL-6 plays an important role in the development of both HIV-positive and HIV-negative MCD; however, the efficacy of tocilizumab in HIV-MCD patients is unknown. We herein report the clinical and biologic courses of two HIV-MCD patients treated with tocilizumab. In both cases, a significant and rapid clinical improvement was observed after the first infusion. However, the treatment efficacy was not maintained for a long period, and relapse occurred at 15 and 22 weeks, respectively. Both patients received rituximab and subsequently achieved complete clinical remission. Our report, in addition to data presented in the literature, suggests that tocilizumab could be an initial treatment option in patients with HIV-MCD.

9 May 2024 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
Azusa NagaoAzusa Nagao
Azusa Nagao
YIYusuke Inagaki
Yusuke Inagaki
KNKeiji Nogami
Keiji Nogami
NYNaoya Yamasaki
Naoya Yamasaki
FIFuminori Iwasaki
Fuminori Iwasaki
HTHideyuki Takedani
Hideyuki Takedani
Joint bleeding can lead to synovitis and arthropathy in people with hemophilia, reducing quality of life. Although early diagnosis is associated with improved therapeutic outcomes, diagnostic ultrasonography requires specialist experience. Artificial intelligence (AI) algorithms may support ultrasonography diagnoses. This study will research, develop, and evaluate the diagnostic precision of an AI algorithm for detecting the presence or absence of hemarthrosis and synovitis in people with hemophilia. Elbow, knee, and ankle ultrasound images were obtained from people with hemophilia from January 2010 to March 2022. The images were used to train and test the AI models to estimate the presence/absence of hemarthrosis and synovitis. The primary endpoint was the area under the curve for the diagnostic precision to diagnose hemarthrosis and synovitis. Other endpoints were the rate of accuracy, precision, sensitivity, and specificity. Out of 5649 images collected, 3435 were used for analysis. The area under the curve for hemarthrosis detection for the elbow, knee, and ankle joints was ≥0.87 and for synovitis, it was ≥0.90. The accuracy and precision for hemarthrosis detection were ≥0.74 and ≥0.67, respectively, and those for synovitis were ≥0.83 and ≥0.74, respectively. Analysis across people with hemophilia aged 10 to 60 years showed consistent results. AI models have the potential to aid diagnosis and enable earlier therapeutic interventions, helping people with hemophilia achieve healthy and active lives. Although AI models show potential in diagnosis, evidence is unclear on required control for abnormal findings. Long-term observation is crucial for assessing impact on joint health.

2 May 2019 in Haemophilia
Verified
Journal Article
Closed access
PDF file
Azusa NagaoAzusa Nagao
Azusa Nagao
NSNobuaki Suzuki
Nobuaki Suzuki
HTHideyuki Takedani
Hideyuki Takedani
NYNaoya Yamasaki
Naoya Yamasaki
YCYushi Chikasawa
Yushi Chikasawa
TSTakashi Suzuki
Takashi Suzuki

18 June 2025 in Haemophilia
Verified
Journal Article
Open access
KAKagehiro Amano
Kagehiro Amano
TFTeruhisa Fujii
Teruhisa Fujii
ASAkihiro Sawada
Akihiro Sawada
Azusa NagaoAzusa Nagao
Azusa Nagao
CNChiai Nagae
Chiai Nagae
KNKeiji Nogami
Keiji Nogami
Background: Emicizumab is approved for routine prophylaxis, but limited data exist investigating the relationship between bleeds and exercise in people with haemophilia A (PwHA) receiving emicizumab. Aim: To evaluate the relationship between physical activity and bleeding outcomes in Japanese PwHA receiving emicizumab prophylaxis. Methods: This prospective, multicentre, observational study was conducted in Japanese PwHA initiating emicizumab between November 2019 and October 2021. Physical activity and bleeding events were reported using an electronic patient‐reported outcomes application, while activity intensity was collected by a wearable activity tracker worn over five 8‐day monitoring periods. Data on safety were recorded by investigators using electronic case report forms. Quality of life data were also collected and will be reported in a separate publication. Results: Overall, 129 participants enrolled. Median age was 32 years (range 0–73), and 83.7% of participants had severe HA. Overall, 73 participants performed 968 exercise events, with 18.8% and 6.0% of events classified as moderate and high risk, respectively. Two (0.2%) exercise events were associated with bleeding: one basketball (moderate risk) and one fishing (low risk). In total, 137 adverse events (AEs) were reported in 62 participants. No serious AEs were emicizumab‐related. The mean annualised treated bleed rate was 1.9 and 51 (39.5%) participants experienced zero bleeds during the study period (97 weeks). Conclusion: This study suggests that PwHA receiving emicizumab prophylaxis can participate in a wide range of physical activities with minimal bleeding risk, which supports their access to the health benefits of exercise. Emicizumab remains well tolerated.

12 June 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
MSMidori Shima
Midori Shima
HTHideyuki Takedani
Hideyuki Takedani
KKKaoru Kitsukawa
Kaoru Kitsukawa
MTMasashi Taki
Masashi Taki
AIAkira Ishiguro
Akira Ishiguro
KNKeiji Nogami
Keiji Nogami
Introduction Persons with haemophilia A (PwHA) commonly experience regular bleeding into joints, which may result in joint damage and complications such as degenerative arthritis. Emicizumab has previously demonstrated efficacy in reducing the occurrence of joint bleeds and target joints, along with having a favourable safety profile; however, data on the long-term effects on joint health are lacking. The AOZORA study will evaluate the long-term safety and joint health of paediatric PwHA without factor (F)VIII inhibitors taking emicizumab; here, we report the details of the study protocol and baseline data. Methods and analysis AOZORA is a multicentre, open-label, phase IV clinical study in Japan that aims to enrol approximately 30 PwHA aged <12 years without FVIII inhibitors. The primary endpoints include a long-term safety evaluation of adverse events, laboratory test abnormalities and FVIII inhibitor development; and a long-term joint health assessment using MRI and the Hemophilia Joint Health Score. Exploratory endpoints include characterising participants’ physical activities and the number of activity-related bleeds requiring coagulation factor treatment. Currently, 30 participants have been enrolled, including 20 emicizumab-naïve participants and 10 who transferred from HOHOEMI, a previous study in paediatric PwHA. Ethics and dissemination The AOZORA study was approved by the Institutional Review Boards of Nara Medical University and the St Marianna University Group. The study will be conducted in compliance with the Declaration of Helsinki, the standards stipulated in paragraph 3 of Article 14 and Article 80-2 of the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act, the Ministerial Ordinance on Good Clinical Practice and the Ministerial Ordinance on Good Post-marketing Study Practice. Data will be published in peer-reviewed journals and presented at Global congresses. Trial registration number JapicCTI-194701.